The Michael J. Fox Foundation LRRK2 Cell Lines Collection
ATCC has been selected by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to provide vital cell lines to academic, pharmaceutical, and biotechnology organizations committed to speed a cure for Parkinson’s disease. We have available macrophage cell lines, including wild-type LRRK2, LRRK2 knockout, and human LRRK2 T1348N (GTPase-dead) knock-in, to advance the understanding of Parkinson’s disease and further drug development toward new therapies for the millions living with this disease.
The Michael J. Fox Foundation SNCA Knockout Isogenic Cell Lines Collection
ATCC is also providing isogenic, CRISPR genome-edited iPSC lines that harbor a triplication, duplication, two copies, single copy, or complete knockout of the α-synuclein (SNCA) gene.
This panel of iPSCs was derived from a donor with an SNCA genomic triplication. The cells were CRISPR-engineered to harbor SNCA frameshift mutations that produce functional knockouts for the alpha-synuclein protein. These lines give Parkinson’s researchers tools to study the effects of varying alpha-synuclein expression levels. Neuroscientists can use these cells to investigate the effect of dosage of the SNCA gene in neurodegenerative diseases.
These cells have been highly characterized by the depositing laboratory and authenticated by ATCC. This panel of isogenic cells are a powerful tool for screening drug candidates that target the SNCA mutant or rescue its phenotype.
